Innovation, Research and Collaboration

Supporting research means giving hope a soil to grow on


Founded in July 2025, the ARON Research Foundation ETS is a global non-profit dedicated to advancing research in genitourinary oncology. We bridge the gap between scientific discovery and clinical practice by fostering specialized education for healthcare professionals and championing equitable access to treatment through global healthcare reporting

Discover More

SUPPORT RESEARCH WITH YOUR 5x1000

With your 5x1000, you choose to support research, to kindle hope, and to give time and a future to those who fight every day.

With just a signature, you can make the difference


TAX CODE: 93097560432

Mission

Our Mission is to create a world where scientific research is accessible to all and where every individual, regardless of their location, is guaranteed equitable access to care. With an approach centered on the global sharing of ideas, we believe in collaborative science and in training a new generation of researchers, doctors, and nurses who support one another in facing daily challenges.

We achieve this by:

  • Supporting clinical and translational research projects to drive innovation in oncology.
  • Mapping global access to care for genitourinary malignancies to identify and bridge treatment gaps.
  • Creating inclusive educational programs dedicated to advancing research and enhancing patient care.
Read More

Vision

Imagine a world that invests in scientific research, making it accessible to all. A world where treatments are equitably available, regardless of geography. A world where, for every new diagnosis, there is a global network of colleagues sharing their expertise—optimizing care and enhancing the quality of life for every patient.

Research, Stories, and Discoveries

We share the latest advancements in research, the personal journeys of those facing the disease, and the newest updates from the ARON world. Every article is a step forward toward knowledge, treatment, and hope.

Immunoterapia: un'arma per prevenire la recidiva di malattia

Immunotherapy: A weapon to prevent disease recurrence

|Francesca Tartari
This study, published in the international journal Cancer Immunology, Immunotherapy in November 2025, analyzed the use of pembrolizumab, an immunotherapy drug, as adjuvant treatment in patients with clear cell renal...
Efficacia di Enfortumab Vedotin nel trattamento di pazienti con carcinoma uroteliale e metastasi ossee

Bone metastases in advanced urothelial carcinoma patients receiving enfortumab vedotin: A Real-World study from the ARON-2EV project

|Francesca Tartari
This study published by “Clinical and Experimental Medicine” Journal examines the effectiveness of enfortumab vedotin, a drug recently approved for the treatment of metastatic urothelial carcinoma (mUC), an advanced form...

Research has a purpose

Every study begins with a question, and the answer can change a life

Commitment that makes a difference

We bring passion and rigor to everything we do, for the patients of today and tomorrow

Together, without borders

A global network of people united by the same vision: a better future through research

News & Events

Le nostre eccellenze: Il Dottor. Alessandro Rizzo vincitore del prestigioso ESMO Merit Award 2026

Celebrating Excellence: Dr. Alessandro Rizzo, Recipient of the Prestigious ESMO Merit Award 2026

|Francesca Tartari
The prestigious award was presented during the ESMO Targeted Anticancer Therapies (TAT) 2026 congress in Paris.
Una nuova frontiera nell’uso dell’immunoterapia e delle terapie a bersaglio al posto della chemioterapia nelle fasi perioperatorie in pazienti con neoplasie vescicali

A new frontier in the use of immunotherapy and targeted therapies instead of chemotherapy in the perioperative setting for patients with bladder cancer

|Francesca Tartari
The study published by Professor Andrea Necchi in the international journal The Lancet Oncology, titled “Neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by adjuvant pembrolizumab, in patients with muscle-invasive bladder cancer...